Introduction {#s1}
============

Heart failure (HF) is a worldwide health issue[@R1] [@R2] resulting in high mortality rates of 40% and 75%, respectively, within the first year[@R3] and at 5 years[@R4] after diagnosis. The treatment of chronic HF has improved in the last decade, with updated national guidelines for diagnosis and disease management. Palliative care (PC) can be initiated when end-stage HF (ESHF) is diagnosed,[@R1] [@R2] with the ratio of PC to life-prolonging care gradually increasing when patients are refractory to treatment.[@R1] [@R5]

Patients with advanced HF experience marked reductions in health-related quality of life (QOL). The three most prevalent physical symptoms reported by these patients are fatigue, dyspnoea and swelling of arms and legs.[@R3] Psychologically, patients with HF experience feelings of uncertainty and fear since their conditions can change rapidly and the feeling of death is imminent.[@R6] Socially, patients with HF feel isolated and lonely,[@R6] and regard themselves as a burden to their carers since they often require assistance in daily living.[@R7] These patients, with complicated issues in refractory symptoms, psychological distress and difficult decision-making involving families, would benefit from a specialist PC team trained in these skills.[@R8] However, PC is reported to be underused among patients with HF.[@R9] [@R10]

The reasons for low use of PC among patients with ESHF are multifactorial, disease-related, person-related and system-related.[@R4] The unpredictable disease trajectories in HF make the prognostication of life span difficult.[@R11] Care providers, including cardiologists and primary care physicians, lack appreciation of the palliative concept and fail to recognise specialist PC as a tangible service.[@R12] Patients are often unaware of PC as a treatment choice.[@R2] At the system level, there is a lack of care coordination in the specialties of HF and PC,[@R4] which may be attributed to suboptimal trust and rapport between providers.[@R12] There need to be clearer guidelines of how and when specialist PC should be integrated into advanced HF management.[@R12]

PC has a long history among patients with cancer. In the last decade, studies have emerged using non-cancer and cancer patients as a study population when testing the effects of PC models. One of the earlier studies was conducted by Brumley *et al*, who tested an in-home PC multidisciplinary intervention programme among patients with cancer, chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF), finding significant reductions in emergency room visits, hospital days and costs compared with a usual care group.[@R11] A systematic review that examined studies involving both cancer and non-cancer patients also showed that multidisciplinary PC support can significantly reduce readmissions, with particularly strong evidence among the HF group.[@R13]

The models for current provision of PC for patients with HF vary, with some hospital-based and others community-based.[@R14] A current review showed that home-based PC interventions among community HF subjects could reduce hospital admissions and enhance symptom management.[@R15] Another study, testing the effects of clinic-based consultations, found that the ability of patients with HF in symptom management was better with more frequent clinic consultations.[@R16] There is a lack of studies exploring the effects of transitional care support for patients with ESHF. Transitional care involves deliberately designed programmes to provide proactive and continuous support to patients returning home after hospital discharge with the intensity and duration of activity events planned with evidence support. Previous studies have demonstrated the effects of transitional care programmes among medical patients in reducing hospital readmissions.[@R17] [@R18] There is no previous transitional programme designed for patients with ESHF and thus no empirical results reporting its effects. The objective of this study was to examine the effects of home-based transitional PC for patients with ESHF after hospital discharge.

Methods {#s2}
=======

Study design {#s2a}
------------

This was a multiple-site randomised controlled trial involving two arms. The intervention group received home visits/telephone calls every week for the first month and less frequently during the subsequent months for a total of 12 months. This study will report results of readmissions up to 12 weeks and other outcomes up to 4 weeks, the initial endpoint after delivery of the intensive intervention. Both groups received usual care, which consisted of PC medical clinic consultation, discharge advice on symptom management and medication and referrals if appropriate (eg, home visits).

Setting and subjects {#s2b}
--------------------

The study took place in three hospitals within the Hospital Authority (HA), Hong Kong between May 2013 and December 2014. The HA is government funded and employs corporate governance which aligns practice within the system. These three hospitals were selected because there were established referral systems between the medical/cardiac and PC teams. Subjects who fulfilled the following criteria were recruited: (a) met two of the following indicators identified as ESHF by the Prognostic Indicator Guidance:[@R19] (i) CHF New York Heart Association (NYHA) stage III or IV, (ii) patient thought to be in the last year of life by clinicians, (iii) repeated hospital admissions (three within 1 year) with symptoms of HF and (iv) existence of physical/psychological symptoms despite optimal tolerated therapy; (b) Cantonese-speaking; (c) living within the service area; (d) contactable by phone and (e) referral accepted by PC team. The exclusion criteria were: (a) discharged to institutions, (b) inability to communicate, (c) diagnosed with severe psychiatric disorders and (d) recruited to other programmes. An advanced practice nurse (APN) helped to screen cases for eligibility (see online [supplementary material](#SM1){ref-type="supplementary-material"}) and confirmed the recruitment with the physician. The patients were approached, and consenting subjects signed a consent form. The responsible APN then called the site investigator for a random assignment generated by the computer software Research Randomizer. The investigator, who had no knowledge of the subject\'s identity, provided the assignment based on sequential computer numbers ('1'=control; '2'=study).

10.1136/heartjnl-2015-308638.supp1

We assumed the effect of our study to be similar to that of a previous study that used home-based palliative follow-up for patients with end-stage organ failure.[@R20] In that study, the average number of 30-day readmissions was reduced from 2.23 to 1.25. By Lehr\'s equation,[@R21] a sample size of 29 per group (=4/(2.23^0.5^−1.25^0.5^)^2^) is adequate to achieve 80% power with a significance level of 0.05. Taking into account a 20% dropout rate, 35 subjects were needed per group.

Intervention {#s2c}
------------

The design of the Transitional Care Palliative-ESHF (TCP-ESHF) programme was based on two main conceptual guides: the recommended principles of PC for patients with HF and the 4Cs for transitional care model. For the principles of PC, the team referenced composite guidelines drawn from Scotland, Europe and Canada,[@R5] [@R22] which could be summarised into the following six principles: (i) case management with periodic review; (ii) discussion of end-of-life issues; (iii) multidisciplinary approach; (iv) staff development for communication, cardiovascular and PC; (v) discussion of treatment preferences and (vi) integrated model of care. The transitional care framework was the 4Cs model tested and used by Wong *et al* with general medical patients.[@R17] [@R18] The 4Cs are comprehensiveness, continuity, coordination and collaboration in alignment with the PC principles mentioned above in providing continuous and coordinated care with multidisciplinary support. Previous studies[@R17] [@R18] have shown that a 4-week intervention with weekly structured events provided a strong enough dose to bring about effects.

The TCP-ESHF was delivered by nurse case managers (NCMs) who were qualified PC home nurses with experience of caring for patients with HF. The NCMs were supported by the PC physician in service delivery. Before a patient\'s discharge, the nurse met the patient/patient\'s family to conduct a predischarge assessment. After discharge, the patient was followed up in the first 4 weeks as below: Week 1---the NCM and trained volunteers (TVs) conducted a home visit together.Week 2---the NCM provided a telephone follow-up.Week 3---the TVs conducted a home visit in pairs.Week 4---the NCM provided a telephone follow-up.

After the first 4 weeks, the subjects in the intervention group received monthly home visits and telephone follow-up until the end of 12 weeks. Based on the Omaha framework,[@R17] the NCM assessed patients' needs in the environmental, psychosocial, physiological and health-related behaviour domains and intervened accordingly. The Omaha system was first developed in the USA and has been tested and used locally.[@R17] [@R18] At each of the encounters, the NCM would set goals and develop a mutually agreed care plan with the patients. The home visits, telephone calls and referrals were governed by protocols to ensure a consistent approach to care delivery. The NCM was assisted by TVs who were nursing students trained in providing patient support.[@R17] [@R18] The NCMs and TVs received 18 and 9 h of training, respectively (see online [supplementary material](#SM1){ref-type="supplementary-material"}).

Placebo calls for the control group {#s2d}
-----------------------------------

The control group received two attention control social calls[@R17] [@R18] from an assistant, consisting of light conversation topics unrelated to clinical issues.

Data collection and measures {#s2e}
----------------------------

Data were collected at discharge (O1), at the primary endpoint at 4 weeks postdischarge (O2) and at the secondary endpoint at 12 weeks for readmission data. The clinical and readmission data were extracted from the hospital information system. The demographic and secondary data were collected by research assistants who were trained and blind to the grouping. The inter-rater reliability reached 0.90.

### Baseline demographic and clinical data {#s2e1}

The demographic data included *age, gender, marital status, education, employment, accommodation* and *economic status.* The clinical data included *aetiology, classification, cardiac surgical intervention received, comorbidity, medications* and *length of stay*.

### Primary data {#s2e2}

The primary data were readmissions within 4 and 12 weeks after the index hospital discharge.

### Secondary data {#s2e3}

*Symptom intensity* was measured by the Edmonton Symptom Assessment Scale (ESAS), which assesses eight symptoms: pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, sense of well-being and dyspnoea using a 0--100 mm visual analogue scale with established validity and Cronbach\'s α reliability of 0.8.[@R23]

*Functional status* was measured by the *Palliative Performance Scale (PPS)*, specifically designed for palliative patients[@R11] to reflect five physical aspects of palliative patients: ambulation, activities, self-care, intake and consciousness level. It has a rating scale from 100 (normal) to 0 (death) measured in 10% decrements with an internal consistency Cronbach\'s α of 0.83.[@R11]

*QOL* was measured by a palliative-specific scale, the McGill quality of life questionnaire-Hong Kong (MQOL-HK) version and an HF-specific scale, the chronic heart failure questionnaire-Chinese (CHQ) version. The MQOL-HK measures four domains (physical, psychological, existential and support) on a numerical scale from 0 to 10, validated for local use with a Cronbach\'s α of 0.83.[@R24] The *CHQ* is a Canadian HF-specific QOL tool measuring 20 items on a 7-point Likert scale representing four domains: dyspnoea, fatigue, emotional status and mastery. It was translated into Chinese and validated with a Cronbach\'s α of 0.95.[@R25]

*Satisfaction with care* was measured by an 11-item questionnaire validated locally with test--retest reliability of 0.87.[@R17]

Data analysis {#s2f}
-------------

### Statistical analysis {#s2f1}

Descriptive statistics were presented to describe the demographic and clinical variables. Poisson regression was used to examine the mean difference in 28-day and 84-day readmission between groups, and the relative risks for the intervention group were examined. The between-group rates were compared using the χ^2^ test. The generalised estimating equation (GEE) was used to examine the group, time and interaction effects on the secondary outcome variables. GEE was used because it treats observations of longitudinal data as correlated, using robust SE estimates to get valid inference.[@R26] The proportion of patients with improvement/deterioration/no change in symptoms (ESAS) was calculated based on the minimal clinically important difference (MCID) cut-off reported in studies by Hui *et al*,[@R27] [@R28] and differences across groups were examined using χ^2^ tests. Both readmissions and MCID were computed based on actual data. The principle of intention to treat was employed and all statistical analyses were conducted using SPSS V.22.0 for Windows.

Results {#s3}
=======

A total of 389 subjects were screened, with 305 excluded. The remaining 84 eligible subjects were randomised. A total of 16 subjects were lost to follow-up (see [figure 1](#HEARTJNL2015308638F1){ref-type="fig"}). [Table 1](#HEARTJNL2015308638TB1){ref-type="table"} displays the demographic and clinical baseline data. The mean age of the subjects was 78.3, with males (52.4%) slightly outnumbering females. The demographic background of the two groups was equivalent. There was no significant between-group difference in clinical parameters, including HF aetiology, mean left ventricular ejection fraction, comorbidity, treatment and medications received, except for the NYHA Class (p=0.03). The perceived health status (PPS and ESAS) at baseline were equivalent in the two groups, and there was no significant difference in their length of hospital stay.

###### 

Baseline demographic and clinical data

  -------------------------------------------------------------------------------------------
                                                      Control\      Intervention\   p Value
                                                      (n=41)        (n=43)          
  --------------------------------------------------- ------------- --------------- ---------
  Age (mean, SD)                                      78.4 (10.0)   78.3 (16.8)     0.99

  Gender                                              0.12                          

   Female                                             16 (39.0%)    25 (56.1%)      

   Male                                               25 (61.0%)    18 (43.9%)      

  Marital status                                      0.83                          

   Married                                            28 (68.3%)    27 (62.8%)      

   Widowed                                            9 (22.1%)     13 (30.2%)      

   Divorced                                           2 (4.8%)      1 (2.3%)        

   Single                                             2 (4.8%)      2 (4.7%)        

  Education                                           0.51                          

   No schooling                                       12 (29.3%)    19 (44.2%)      

   Primary                                            20 (48.8%)    16 (37.2%)      

   Secondary                                          7 (17.1%)     7 (16.3%)       

   University                                         2 (4.9%)      1 (2.3%)        

  Employment                                          0.42                          

   In employment                                      1 (2.4%)      1 (2.3%)        

   Retired/housewife                                  40 (97.6%)    42 (97.7%)      

  Household                                           0.29                          

   Living alone                                       5 (12.2%)     2 (4.7%)        

   Living with family                                 36 (87.8%)    41 (95.3%)      

   Number of family members (mean, SD)                3 (1.4)       3 (1.5)         0.07

  Housing type                                        0.58                          

   Rental                                             5 (12.2%)     5 (11.6%)       

   Private                                            10 (24.4%)    14 (32.6%)      

   Public/staff quarters                              26 (63.4%)    24 (55.8%)      

  Perceived economic status                           0.74                          

   More than enough                                   10 (24.4%)    11 (25.6%)      

   Just enough                                        20 (48.8%)    25 (58.1%)      

   Not enough                                         11 (26.8%)    7 (16.3%)       

  Chronic heart failure aetiology                                                   

   Ischaemic heart disease                            23 (56.1%)    30 (69.8%)      0.19

   Hypertension                                       22 (53.7%)    29 (67.4%)      0.20

   Cardiomyopathy                                     4 (9.8%)      3 (7.0%)        0.65

   Heart valve disease                                9 (22.0%)     5 (11.6%)       0.20

   Arrhythmias                                        23 (56.1%)    18 (41.9%)      0.19

   Congenital heart defects                           1 (2.4%)      0 (0)           0.30

  New York Heart Association Class                    0.03                          

   II                                                 3 (7.3%)      6 (14.0%)       

   III                                                22 (53.7%)    31 (72.1%)      

   IV                                                 16 (39.0%)    6 (14.0%)       

  Left ventricular ejection fraction (mean, SD)       37 (17)       39 (14)         0.57

  Cardiac surgical intervention received                                            

   Coronary artery bypass graft surgery               3 (7.3%)      2 (4.7%)        0.61

   Cardiac catheter                                   15 (36.6%)    12 (27.9%)      0.39

   Cardiac resynchronisation therapy                  4 (9.8%)      0 (0)           0.04

   Implantable cardioverter defibrillator             3 (7.3%)      1 (2.3%)        0.28

   Percutaneous coronary intervention                 11 (26.8%)    10 (23.3%)      0.71

   Permanent pace maker                               9 (22.0%)     2 (4.7%)        0.02

   Valve surgery                                      5 (12.2%)     4 (9.3%)        0.67

  Comorbidity                                                                       

   Asthma                                             3 (7.3%)      4 (9.3%)        0.74

   Chronic obstructive pulmonary disease              5 (12.2%)     2 (4.7%)        0.21

   Cancer                                             5 (12.2%)     7 (16.3%)       0.59

   Diabetes                                           15 (36.6%)    20 (46.5%)      0.36

   Hyperlipidaemia                                    9 (22.0%)     18 (41.9%)      0.051

   Myocardial infarction                              13 (31.7%)    17 (39.5%)      0.45

   Stroke                                             7 (17.1%)     7 (16.3%)       0.92

   Renal impairment                                   18 (43.9%)    26 (60.5%)      0.13

  Medications                                                                       

   ACE inhibitors                                     12 (29.3%)    17 (39.5%)      0.32

   Anticoagulants                                     9 (22.0%)     8 (18.6%)       0.70

   Aldosterone receptor antagonists                   10 (24.4%)    10 (23.3%)      0.90

   ARBs                                               2 (4.9%)      3 (7.0%)        0.68

   β blockers                                         13 (31.7%)    17 (39.5%)      0.45

   Calcium channel blockers                           1 (2.4%)      6 (14.0%)       0.06

   Digoxin                                            7 (17.1%)     6 (14.0%)       0.69

   Diuretics                                          24 (58.5%)    26 (60.5%)      0.86

   Statins                                            1 (2.4%)      4 (9.3%)        0.18

  Length of stay at index admission (median, range)   6 (1--37)     5 (2--66)       0.93

  PPS                                                                               

   Ambulation                                         32 (78.0%)    35 (81.4%)      0.70

   Activity                                           41 (100.0%)   43 (100.0%)     N/A

   Self-care                                          19 (46.3%)    25 (58.1%)      0.28

   Intake                                             39 (95.1%)    43 (100.0%)     0.14

   Conscious level                                    19 (46.3%)    25 (58.1%)      0.28

   Overall (mean, SD)                                 6.6 (1.2)     6.4 (1.0)       0.55

  ESAS                                                                              

   Pain                                               21 (51.2%)    27 (62.8%)      0.28

   Tiredness                                          39 (95.1%)    42 (97.7%)      0.53

   Nausea                                             3 (7.3%)      4 (9.3%)        0.74

   Depression                                         28 (68.3%)    27 (62.8%)      0.60

   Anxiety                                            30 (73.2%)    29 (67.4%)      0.57

   Drowsiness                                         7 (17.1%)     8 (18.6%)       0.86

   Loss of appetite                                   37 (90.2%)    35 (81.4%)      0.25

   Sense of well-being                                39 (95.1%)    40 (93.0%)      0.68

   Dyspnoea                                           34 (82.9%)    37 (86.0%)      0.69

   Total                                              33.0 (12.7)   35.5 (13.6)     0.38
  -------------------------------------------------------------------------------------------

ARBs, angiotensin-receptor blockers; ESAS, Edmonton Symptom Assessment Scale; PPS, Palliative Performance Scale.
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The intervention group had a lower 4-week readmission rate (intervention 20.9% vs control 29.3% χ^2^=4.41, p=0.79) and mean number of readmissions (intervention 0.21 (SE 0.07) vs control 0.41 (SE 0.10) p=0.097), but the difference was not significant. At 12 weeks, the readmission rate (intervention 33.6% vs control 61.0% χ^2^=6.8, p=0.009) and mean number of readmissions (intervention 0.42 (SE 0.10) vs control 1.10 (SE 0.16), p=0.001) became significantly lower for the intervention group (see [table 2](#HEARTJNL2015308638TB2){ref-type="table"}). The relative risks (CI) for 4-week and 12-week readmissions for the intervention group were, respectively, 0.81 (0.51 to 1.27) and 0.55 (0.35 to 0.88).

###### 

Readmission at 4 and 12 weeks

  -------------------------------------------------------------------------------------------
                                                      Control\      Intervention\   p Value
                                                      (n=41)        (n=43)          
  --------------------------------------------------- ------------- --------------- ---------
  Number of readmissions at 4 weeks (mean, SE)        0.41 (0.10)   0.21 (0.07)     0.10

  Number of readmissions at 12 weeks (mean, SE)\*\*   1.10 (0.16)   0.42 (0.10)     0.001

  Readmissions within 28 days (n, %)                                                

   No                                                 29 (70.7%)    34 (79.1%)      0.38

   Yes                                                12 (29.3%)    9 (20.9%)       

  Readmissions within 84 days (n, %)\*                                              

   No                                                 16 (39.0%)    29 (67.4%)      0.009

   Yes                                                25 (61.0%)    14 (33.6%)      
  -------------------------------------------------------------------------------------------

Tested using Poisson regression and χ^2^ test. \*p\<0.05; \*\*p\<0.01.

The MCID of the symptom intensity was examined. Compared with the control group, the intervention group experienced significantly higher clinical improvement in depression (45.9% vs 16.1%, p\<0.05), dyspnoea (62.2% vs 29.0%, p\<0.05) and total score (73.0% vs 41.4%, p\<0.05) ([table 3](#HEARTJNL2015308638TB3){ref-type="table"}).

###### 

Change in ESAS at O2 (n=68)

                                      Control (n=31)   Intervention (n=37)                             
  ---------------------- ------------ ---------------- --------------------- ------------ ------------ ------------
  Frequency (%)                                                                                        
   Pain                  10 (32.3%)   11 (35.5%)       10 (32.3%)            8 (21.6%)    15 (40.5%)   14 (37.8%)
   Tiredness             11 (35.5%)   10 (32.3%)       10 (32.3%)            7 (18.9%)    13 (35.1%)   17 (45.9%)
   Nausea                1 (3.2%)     30 (96.8%)       0 (0.0%)              1 (2.7%)     34 (91.9%)   2 (5.4%)
   Depression\*          11 (35.5%)   15 (48.4%)       5 (16.1%)             7 (18.9%)    13 (35.1%)   17 (45.9%)
   Anxiety               8 (25.8%)    16 (51.6%)       7 (22.6%)             8 (21.6%)    13 (35.1%)   16 (43.2%)
   Drowsiness            3 (9.7%)     25 (80.6%)       3 (9.7%)              1 (2.7%)     31 (83.8%)   5 (13.5%)
   Loss of appetite      10 (32.3%)   9 (29.0%)        12 (38.7%)            7 (18.9%)    16 (43.2%)   14 (37.8%)
   Sense of well-being   14 (45.2%)   10 (32.3%)       7 (22.6%)             14 (37.8%)   9 (24.3%)    14 (37.8%)
   Dyspnoea\*            10 (32.3%)   12 (38.7%)       9 (29.0%)             7 (18.9%)    7 (18.9%)    23 (62.2%)
   Total\*               12 (41.4%)   5 (17.2%)        12 (41.4%)            7 (18.9%)    3 (8.1%)     27 (73.0%)

Tests using χ^2^; \*p\<0.05.

Note: the MCID cut-offs for improvement/deterioration of each symptom[@R27] and total[@R28] were: pain 1.4/−1, tiredness 1.5/−1.5, nausea 1.6/−2.3, depression 1/−1.8, anxiety 1.7/−1.4, drowsiness 0.8/−2, loss of appetite 1.2/−2.1, sense of well-being 1.2/−0.8, dyspnoea 1.2/−1.3 and total 5.7/−2.9.

ESAS, Edmonton Symptom Assessment Scale; MCID, minimal clinically important difference.

[Table 4](#HEARTJNL2015308638TB4){ref-type="table"} displays the results of the secondary outcome comparing the baseline and week 4. There was no difference in functional status (PPS) within or between groups over time. There was some improvement in the symptom intensity of depression and anxiety as measured by ESAS over time in the intervention group, but there was no difference in improvement between groups. Both measures of QOL, the Chronic heart-failure questionnaire Chinese (CHQC) (p\<0.01) and McGill QOL (p\<0.05), showed a significant difference in the change over time between groups. When individual items were examined, all achieved statistically significant difference with group-time effect, except for 'fatigue' in CHQC and 'physical' and 'existential' in McGill. The intervention group had significantly higher satisfaction with care than the control group (p\<0.001).

###### 

Secondary outcomes at O1 and O2

                                                     Control (n=41)   Intervention (n=43)                   
  -------------------------------------------------- ---------------- --------------------- --------------- --------------------
  Palliative performance scale (%, SE)                                                                      
   Ambulation                                        79.6 (25.2)      69.2 (33.4)           82.2 (22.7)     76.0 (28.4)
   Activity                                          100.0 (0.0)      100.0 (0.0)           100.0 (0.0)     100.0 (0.0)
   Self-care                                         45.6 (44.1)      30.8 (38.1)           59.8 (42.7)     40.5 (42.9)
   Intake                                            90.0 (6.0)       91.9 (5.2)            91.9 (4.9)      89.8 (6.2)
   Conscious level                                   45.6 (44.1)      30.8 (38.1)           59.8 (42.7)     40.5 (42.9)
   Overall                                           65.5 (18.0)      66.8 (18.9)           64.72 (15.13)   66.85 (18.67)
  Edmonton Symptom Assessment System (%, SE)                                                                
   Pain                                              51.5 (44.6)      42.0 (43.9)           63.1 (40.6)     56.4 (44.0)
   Tiredness                                         90.0 (7.0)       91.6 (6.9)            91.0 (6.3)      89.8 (7.2)
   Nausea                                            11.1 (9.4)       10.8 (9.4)            12.1 (10.1)     9.1 (7.9)
   Depression                                        70.9 (35.5)      58.0 (42.2)           65.1 (39.0)     36.4 (33.5)\*\*
   Anxiety                                           75.5 (31.6)      50.0 (43.1)           70.0 (35.9)     34.5 (38.8)\*\*
   Drowsiness                                        16.8 (17.2)      14.4 (15.4)           17.8 (18.0)     9.1 (10.2)
   Loss of appetite                                  87.6 (15.9)      75.7 (27.4)           82.2 (21.5)     68.3 (31.9)
   Sense of well-being                               90.0 (9.2)       89.2 (10.0)           89.0 (9.9)      85.7 (12.5)
   Dyspnoea                                          83.2 (20.3)      81.1 (22.5)           85.2 (18.3)     71.0 (30.0)
   Total                                             35.13 (2.15)     32.39 (3.20)          33.32 (1.93)    23.97 (2.20)\*\*\*
  Chronic Heart Failure Questionnaire (score, SE)                                                           
   Dyspnoea\*\*                                      4.83 (0.18)      4.89 (0.28)           4.65 (0.17)     5.82 (0.19)\*\*\*
   Fatigue                                           3.64 (0.20)      3.77 (0.24)           3.80 (0.20)     4.19 (0.26)
   Emotional\*\*                                     4.86 (0.24)      4.61 (0.29)           5.09 (0.19)     5.68 (0.17)\*\*
   Mastery\*\*                                       4.58 (0.22)      4.64 (0.26)           4.30 (0.22)     5.36 (0.22)\*\*\*
   Total\*\*                                         4.49 (0.15)      4.47 (0.23)           4.45 (0.14)     5.26 (0.17)\*\*\*
  McGill Quality of Life Questionnaire (score, SE)                                                          
   Physical                                          4.07 (0.25)      4.79 (0.33)\*         4.48 (0.25)     5.72 (0.35)\*\*\*
   Psychological\*                                   7.63 (0.33)      7.71 (0.48)           7.82 (0.30)     9.06 (0.23)\*\*\*
   Existential                                       5.61 (0.45)      5.86 (0.50)           6.01 (0.38)     7.17 (0.35)\*\*
   Support\*                                         8.05 (0.30)      7.82 (0.39)           7.87 (0.32)     8.57 (0.25)\*
   Overall\*                                         6.33 (0.33)      6.16 (0.44)           6.41 (0.32)     7.37 (0.29)\*
   Total\*                                           6.35 (0.23)      6.46 (0.36)           6.51 (0.22)     7.57 (0.21)\*\*\*
  Satisfaction with care (score, SE)\*\*\*           N/A              36.55 (2.09)          N/A             48.84 (1.82)

Tests using generalised estimating equation (GEE); \*p\<0.05; \*\* p\<0.01; \*\*\*p\<0.001.

Discussion {#s4}
==========

This study adds to the evidence that an intensive 4-week transitional home-based programme sustained by monthly follow-up is effective in reducing readmissions, controlling symptoms and enhancing QOL among patients with ESHF on returning home after hospital discharge.

The design of the TCP-ESHF programme in this study contained evidence-based elements identified by a current systematic review that were found to be effective in reducing hospital readmissions. They were the use of multicomponents in interventions involving a multidisciplinary team in care delivery and supporting clients to optimise capacity for self-care.[@R29] Few transitional care studies have been conducted among patients with ESHF. Brumley *et al* tested a palliative programme among non-cancer patients, including HF and COPD subjects, finding that an in-home PC group had higher satisfaction and fewer hospitalisations than a usual care group.[@R11] This study obtained the same results and was also consistent with other trials in demonstrating that a home-based PC programme could enhance QOL.[@R1] [@R12] As in other studies,[@R1] [@R9] dyspnoea and fatigue were two common symptoms reported by subjects in this study. The NCMs in this study were able to empower their patients in symptom management, make adjustments to medications and offer early referral if appropriate.[@R11] [@R18] Previous studies that examined the effects of palliative home-based support focused on patients in the community who were referred for home care.[@R11] [@R20] This study shows that transitional care support after an episode of hospitalisation enabled patients to reduce hospital use and stay well in the community. Similar transitional care programmes, led by professionals and supported by volunteers, have proved cost-effective among general medical patients.[@R30]

Patients with ESHF have typical PC needs that include symptom control and psychosocial support.[@R31] The use of PC among patients with HF is low,[@R9] as reflected by the low statistics that ranged from only 5% for non-cancer[@R10] to 12% for HF[@R32] users of hospice services. One of the challenges in referring patients with HF to PC services is the unpredictable illness trajectory of HF, which makes accurate prognostication difficult.[@R33] Advocacy of the PC approach in HF treatment guidelines helps remind clinicians to adopt this approach when appropriate and in the best interests of patients.[@R32] The triggering of the palliative approach needs the collaboration of both PC and medical specialists.[@R9] This study benefited from explicit referral guidelines developed in the study sites, supported by the medical/cardiac team and hospital management.

Stuart asserts that the alignment of financial incentives between specialties and across healthcare settings is important, particularly when the provision of care needs to extend from hospital to home.[@R32] Having an innovative infrastructure design is important in helping to integrate the PC approach into the continuum of HF care.[@R4] The design of the TCP-ESHF achieved the delivery of services that were comprehensive and coordinated in collaboration with a team comprising professionals and volunteers supporting patients with continuity. When the biomedical curative approach of adding years to life is no longer possible, the holistic approach of PC to control symptoms and address patients' needs is a preferred alternative.[@R4]

This study has a number of limitations. The loss of follow-up was high, which is not uncommon among palliative patients. The rate was 24.4% and 14.0%, respectively, for the control and intervention groups, the main reasons being death and deterioration. The sample size was relatively small and there was a significantly higher NYHA class in the control compared with the intervention group. The study was conducted in Hong Kong, whose healthcare system differs from those in other countries. Repeated studies should be conducted both within and outside Hong Kong with larger sample sizes to confirm the internal and external validity of the findings. This study has focused on administrative outcomes, namely hospital readmissions. No existing studies have reported MCID for QOL, which is an important outcome measure for palliative patients. This study used symptom measures to calculate MCID, which fails to reflect the clinically important overall well-being of the patients.

Conclusions {#s5}
===========

This study has provided evidence of the effects of a postdischarge home-based palliative programme in reducing readmissions and enhancing QOL among patients with ESHF. The shifting of the focus from treatment to symptom control in the continuum of care requires the support of both cardiologists and PC physicians in building a referral mechanism and service model in the delivery of care. Home care nurses who are experienced in PC as well as HF symptom management are instrumental in providing continuity of care for patients immediately after hospital discharge. The nurse\'s access to both physician and multidisciplinary team is essential in providing early intervention when problems are detected.

###### Key messages

What is already known on this subject?
--------------------------------------

-   Palliative care enhances quality at the end of life among patients with cancer.

-   Transitional care support after hospital discharge reduces readmissions and enhances clients' quality of life.

What might this study add?
--------------------------

-   Specialist palliative care is beneficial to non-cancer patients who are at the end-stage of organ failure.

-   Transitional care support, led by professionals supported by volunteers, can reduce hospital readmissions, enhance quality of life and achieve significantly higher clinical improvement in symptom control among patients with end-stage heart failure.

How might this impact on clinical practice?
-------------------------------------------

-   Patients with heart failure at an advanced stage and refractory to medical therapy would benefit from specialist palliative care.

-   The deliberate design of transitional care support for patients with end-stage heart failure requires organisational support to develop clear referral guidelines between medical and palliative care physicians, and mobilising resources to ensure continuity of care extended from hospital to home.
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